PMC:7650537 / 13586-16366 JSONTXT 8 Projects

Annnotations TAB TSV DIC JSON TextAE

Id Subject Object Predicate Lexical cue
T103 0-4 Sentence denotes 3.1.
T104 5-64 Sentence denotes Performance of Eight SARS-CoV-2 IgG or Total Antibody Tests
T105 65-213 Sentence denotes Thirty-seven samples taken from patients with a PCR-confirmed SARS-CoV-2 infection were analyzed with eight SARS-CoV-2 IgG or total antibody assays.
T106 214-357 Sentence denotes Samples #1, #7, and #9 were taken nine days before to four days after PCR and were all found to be free of SARS-CoV-2 antibodies by the assays.
T107 358-470 Sentence denotes These samples were not considered for calculation of the sensitivity but demonstrated seroconversion (Figure 1).
T108 471-571 Sentence denotes Out of the remaining 34 samples, only one serum (#20; Figure 1), which was obtained from patient no.
T109 572-681 Sentence denotes 12 ten days after a positive RT-PCR, tested negative for SARS-CoV-2 IgG/total antibodies in the eight assays.
T110 682-730 Sentence denotes However, this sample exhibited a PRNT 1:10–1:20.
T111 731-796 Sentence denotes All other samples were reactive in at least one assay (Figure 1).
T112 797-912 Sentence denotes Twenty (76.9%) patients developed virus-neutralizing antibodies, as shown by a PRNT >1:10 (Figure 1 and Figure S1).
T113 913-1054 Sentence denotes With respect to the SARS-CoV-2 PCR (reference 1) or the PRNT results (reference 2), assay sensitivities ranged from 80.8% to 96.3% (Table 1).
T114 1055-1155 Sentence denotes Specificity was calculated using 100 archived samples that should not contain SARS-CoV-2 antibodies.
T115 1156-1212 Sentence denotes A total of ten sera were reactive in one or more assays.
T116 1213-1288 Sentence denotes None contained SARS-CoV-2 neutralizing antibodies (Figure 2 and Figure S1).
T117 1289-1434 Sentence denotes The residual 90 stored samples were not tested in the PRNT, as they were found to be free of SARS-CoV-2 IgG/total antibodies in all eight assays.
T118 1435-1540 Sentence denotes Thus, assay specificities ranged from 96.0% to 100%, and accuracies varied from 93.7% to 99.2% (Table 1).
T119 1541-1695 Sentence denotes Twelve routine samples obtained from individuals who were interested in their SARS-CoV-2 antibody status were re-evaluated by all eight assays (Figure 3).
T120 1696-1777 Sentence denotes Six of them—including three family members of the SARS-CoV-2-infected patient no.
T121 1778-1876 Sentence denotes 14 (Figure 1)—were classified SARS-CoV-2 IgG/total antibody-positive by the majority of the tests.
T122 1877-1935 Sentence denotes Isolated reactivity was observed in three sera (Figure 3).
T123 1936-2117 Sentence denotes Twenty-four (92.3%) of the 26 SARS-CoV-2 infected patients were reactive in one or both versions of the IgG recomLine assay; the test results differed only in three sera (Figure 1).
T124 2118-2352 Sentence denotes One out of the ten archived sera that were reactive in at least one of the SARS-CoV-2 IgG/total antibody tests was also classified as SARS-CoV-2 IgG-positive by the prototype immunoblot (v1) but was negative in the improved version 2.
T125 2353-2603 Sentence denotes The underlying sample #7 was collected in the winter 2018/2019 and was found to be reactive for SARS-CoV-2 IgG/total antibodies by the Mikrogen (S/CO 1.33), Roche (S/CO 3.46), and Viramed (N antigen 125 ViraChip® Units) assays in parallel (Figure 2).
T126 2604-2780 Sentence denotes The twelve routine samples were analyzed by both versions of the blot (v1: nine samples and v2: all samples), and results of the immunoassays were largely confirmed (Figure 3).